Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN21353 · 1 trial · 2 indications
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose expansion
| Arm | Type | Description |
|---|---|---|
| Module 1: monotherapy | EXPERIMENTAL | - |
| Module 2: combination | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN21353 | DRUG | Administered per the protocol |
| Nezastomig | DRUG | Administered per the protocol |
| Sarilumab Prophylaxis (Contingency) | DRUG | May be administered as pretreatment, per the protocol |
Key Inclusion Criteria: 1. Is male with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma 2. Has metastatic castration-resistant prostate cancer with prostate-specific antigen value as described in the protocol and that has progressed within ...
REGN21353 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. for metastatic castration-resistant prostate cancer (mCRPC). It is in Phase 1 clinical development and is being studied both as a single agent and in combination with nezastomig in adult male participants.
REGN21353 is being developed for the treatment of metastatic castration-resistant prostate cancer, also called mCRPC. This is an advanced form of prostate cancer that has spread beyond the prostate and no longer responds to androgen deprivation therapy. The drug remains investigational and has not been approved for any use.
REGN21353 is developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical program evaluating the small molecule in metastatic castration-resistant prostate cancer.
REGN21353 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program is evaluating the drug in adult male participants with metastatic castration-resistant prostate cancer.
REGN21353 is being evaluated in one Phase 1 trial, NCT07850921, titled REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants. The study is not yet recruiting, is controlled, and plans to enroll 192 participants aged 18 years and older.
Yes. The Phase 1 trial NCT07850921 evaluates REGN21353 both as a single agent and in combination with nezastomig in adults with metastatic castration-resistant prostate cancer. The study is controlled and is not yet recruiting, with a planned enrollment of 192 male participants.